-
At least 7 dead after UPS cargo plane crashes near Louisville airport
-
US Supreme Court hears challenge to Trump tariff powers
-
US government shutdown becomes longest in history
-
India's Modi readies bellwether poll in poorest state
-
Green goals versus growth needs: India's climate scorecard
-
Where things stand on China-US trade after Trump and Xi talk
-
Sri Lanka targets big fish in anti-corruption push
-
NY elects leftist mayor on big election night for Democrats
-
Injured Jordie Barrett to miss rest of All Blacks tour
-
Asian markets tumble as tech bubble fears grow
-
Pay to protect: Brazil pitches new forest fund at COP30
-
Australia pick 'impressive' Weatherald in first Ashes Test squad
-
Iraq's social media mercenaries dying for Russia
-
Young leftist Trump foe elected New York mayor
-
Concerns at ILO over expected appointment of close Trump advisor
-
Venus Williams to return to Auckland Classic at the age of 45
-
No deal yet on EU climate targets as COP30 looms
-
Typhoon death toll climbs to 66 in the Philippines
-
NATO tests war preparedness on eastern flank facing Russia
-
Uncapped opener Weatherald in Australia squad for first Ashes Test
-
Liverpool down Real Madrid in Champions League, Bayern edge PSG
-
Van Dijk tells Liverpool to keep calm and follow Arsenal's lead
-
PSG left to sweat on injuries to Dembele and Hakimi
-
Reddit, Kick to be included in Australia's social media ban
-
Ex-Zimbabwe cricket captain Williams treated for 'drug addiction'
-
Padres ace Darvish to miss 2026 MLB season after surgery
-
Diaz hero and villain as Bayern beat PSG in Champions League showdown
-
Liverpool master Real Madrid on Alexander-Arnold's return
-
Van de Ven back in favour as stunning strike fuels Spurs rout
-
Juve held by Sporting Lisbon in stalling Champions League campaign
-
New lawsuit alleges Spotify allows streaming fraud
-
Stocks mostly drop as tech rally fades
-
LIV Golf switching to 72-hole format in 2026: official
-
'At home' Djokovic makes winning return in Athens
-
Manchester City have become 'more beatable', says Dortmund's Gross
-
Merino brace sends Arsenal past Slavia in Champions League
-
Djokovic makes winning return in Athens
-
Napoli and Eintracht Frankfurt in Champions League stalemate
-
Arsenal's Dowman becomes youngest-ever Champions League player
-
Cheney shaped US like no other VP. Until he didn't.
-
Pakistan edge South Africa in tense ODI finish in Faisalabad
-
Brazil's Lula urges less talk, more action at COP30 climate meet
-
Barca's Lewandowski says his season starting now after injury struggles
-
Burn urges Newcastle to show their ugly side in Bilbao clash
-
French pair released after 3-year Iran jail ordeal
-
EU scrambles to seal climate targets before COP30
-
Getty Images largely loses lawsuit against UK AI firm
-
Cement maker Lafarge on trial in France over jihadist funding
-
Sculpture of Trump strapped to a cross displayed in Switzerland
-
Pakistan's Rauf and Indian skipper Yadav punished over Asia Cup behaviour
US panel weighs authorizing Covid vaccines for youngest children
After months of anxious wait for some parents, a panel of experts convened by the US Food and Drug Administration will meet Wednesday to weigh recommending Covid vaccines for the nation's youngest children.
Children under five are the only age group not yet eligible for Covid immunization in the United States and most other countries. If, as expected, panelists vote in favor of greenlighting the Pfizer and Moderna vaccines, formal authorizations should follow quickly, with the first shots in arms expected by next week.
Ahead of the meeting, the FDA posted its independent analyses of the two drugs, deeming both safe and effective. It also said there was a pressing unmet need to inoculate children in the age group since their rates of hospitalization and death "are higher than among children and adolescents 5-17 years of age."
Both vaccines are based on messenger RNA technology, which delivers genetic code for the coronavirus spike protein to human cells, training the immune system to be ready for when it encounters the real virus.
Pfizer is seeking authorization for three doses at three micrograms given to ages six months through four years, while Moderna has asked for the FDA to approve its vaccine as two doses of a higher 30 micrograms, for ages six months through five years.
They were tested in trials of thousands of children where they were found to have similar levels of mild effects to older age groups and triggered similar levels of antibodies.
Efficacy against infection was higher for Pfizer, with the company placing it at 80 percent compared to Moderna's estimates of 51 percent in the six-month-old to age two group and 37 percent in the two to five years age group.
But the figures are provisional and Moderna is studying adding a third dose later that may increase its figures.
There are some 20 million US children aged four years and under. If the FDA-appointed experts recommend the two vaccines, then the matter will go to another committee convened by the Centers for Disease Control and Prevention for a final say.
White House officials last week said the rollout of millions of shots at pharmacies and doctors' offices could begin as soon as June 21, following the Juneteenth holiday on June 20.
Of the total US Covid deaths, 480 have come in children under five, according to the latest official data.
Obesity, neurological disorders and asthma are associated with increased risk of severe disease, "however, a majority of children hospitalized for Covid-19 have no underlying medical conditions," the FDA said in a document.
Children can also go on to contract multisystem inflammatory syndrome in children (MIS-C), a rare but serious post-viral condition.
Data on long Covid in children is sparse, but the FDA's document cited a national survey in the United Kingdom which found that "among children ages two to 11 years who tested positive for COVID-19, 7.2 percent reported continued symptoms at 12 weeks."
J.AbuHassan--SF-PST